首页> 外文期刊>Chest: The Journal of Circulation, Respiration and Related Systems >Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.
【24h】

Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.

机译:肺癌患者经放射支气管内超声引导经支气管针抽吸淋巴结和正电子发射断层扫描正常纵隔。

获取原文
获取原文并翻译 | 示例
           

摘要

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) can reliably sample enlarged mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC), and in practice is mostly used to sample nodes visible on CT or positron emission tomography (PET). Few data are available on the use of endoscopic procedures to stage the mediastinum in clinical stage 1 lung cancer. The aim of the present study was to determine the results of EBUS-TBNA in sampling mediastinal lymph nodes in patients with lung cancer and a radiographically normal mediastinum and no PET activity. From January 2004 to May 2007, patients highly suspicious for NSCLC with CT scans showing no enlarged lymph nodes (no node > 1 cm) and a negative PET finding of the mediastinum underwent EBUS-TBNA. Identifiable lymph nodes at locations 2r, 2L, 4r, 4L, 7, 10r, 10L, 11r, and 11L were aspirated. All patients underwent subsequent surgical staging. Diagnoses based on aspiration results were compared with those based on surgical results. One hundred patients (mean age, 52.4 years; 59 men) were included. After surgery, 97 patients (mean age, 52.9 years; 57 men) had NSCLC confirmed and were included in the analysis. In this group, 156 lymph nodes ranging 5 to 10 mm in size were detected and sampled. Malignancy was detected in nine patients but missed in one patient. Mean diameter of the punctured lymph nodes was 7.9 mm. The sensitivity of EBUS-TBNA for detecting malignancy was 89%, specificity was 100%, and the negative predictive value was 98.9%. No complications occurred. In conclusion, EBUS-TBNA can be used to accurately sample and stage patients with clinical stage 1 lung cancer and no evidence of mediastinal involvement on CT and PET. Potentially operable patients with no signs of mediastinal involvement may benefit from presurgical staging with EBUS-TBNA.
机译:支气管内超声引导下经支气管针吸术(EBUS-TBNA)可以可靠地取样非小细胞肺癌(NSCLC)患者的纵隔淋巴结肿大,并且在实践中通常用于取样在CT或正电子发射断层扫描(PET)上可见的淋巴结)。关于使用内窥镜手术在临床1期肺癌中进行纵隔分期的数据很少。本研究的目的是确定EBUS-TBNA在肺癌和放射学上正常的纵隔且无PET活性的患者的纵隔淋巴结取样中的结果。从2004年1月至2007年5月,高度怀疑NSCLC的患者接受了EBUS-TBNA的CT扫描,显示无淋巴结肿大(无结节> 1 cm),纵隔PET阴性。抽吸位于位置2r,2L,4r,4L,7、10r,10L,11r和11L的可识别淋巴结。所有患者均接受随后的手术分期。将基于抽吸结果的诊断与基于手术结果的诊断进行了比较。包括一百名患者(平均年龄,52.4岁; 59名男性)。手术后,有97例(平均年龄52.9岁; 57例男性)确诊为NSCLC,并纳入分析。在该组中,检测并采样了156个大小为5至10 mm的淋巴结。在9例患者中发现了恶性肿瘤,但在1例中未发现恶性肿瘤。穿刺淋巴结的平均直径为7.9 mm。 EBUS-TBNA检测恶性肿瘤的敏感性为89%,特异性为100%,阴性预测值为98.9%。无并发症发生。总之,EBUS-TBNA可以用于对临床1期肺癌且没有CT和PET纵隔累及迹象的患者进行准确采样和分期。没有纵隔受累迹象的潜在可手术患者可受益于EBUS-TBNA的术前分期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号